Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, ...
For more than a decade, Olivia Ferro, 26, struggled with health issues and a medical system that couldn’t seem to figure out what was wrong with her. She gained weight and suffered excruciating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results